Home › Medicare GLP-1 Providers › Medicare GLP-1 Bridge Denied

Best GLP-1 Provider After Medicare Bridge Denial: Who Can Actually Help

By the WPG Research Team · Last verified: August 5, 2026

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

Advertising disclosure: Some links below are affiliate links, and we may earn a commission if you sign up. Affiliate status is not part of our ranking. The first paths we recommend — your current prescriber, the correct Medicare route, and manufacturer-direct cash programs — may pay us nothing.

Bottom line up front

The best GLP-1 provider after Medicare Bridge denial depends entirely on why you were denied — and for most people, the right answer is the doctor you already have.

A denial closes one door. There are four.

If your pharmacy just said “prior authorization required,” you probably were not denied at all. That is the normal first step after an eligible Bridge claim reaches the central processor. If a real denial came back because a form was wrong or a record was missing, your prescriber may send corrected, updated, or additional information. If your prescription belongs under regular Part D because of diabetes, moderate-to-severe sleep apnea, MASH, or another Part D-covered use, you need the Part D door instead. And if you truly do not qualify, current manufacturer cash programs start at $149 a month for Wegovy pill or Foundayo and $299 a month for Zepbound. Higher doses and refill-timing rules can raise the price.

Here is the part almost nobody tells you, and it is the reason we built this page: the commercial savings cards we audited exclude Medicare. The manufacturer self-pay programs are separate, and their current terms do not use the same blanket Medicare exclusion. You pay cash, do not submit the charge to Medicare, and do not count it toward your deductible or out-of-pocket total. Those rules sit close together on the same manufacturer pages. We read both sets.

→ Find out which door is open for you — five questions, about 60 seconds. No Medicare number. No Social Security number. No email.

Sources: CMS provider guidance, NovoCare Wegovy pricing, Lilly Zepbound pricing, and Lilly Foundayo pricing.

Before you spend a dollar: our honest warning

Most people reading this should not pay a telehealth company anything.

We are an affiliate site. We get paid when you sign up with some providers. So understand what it means when we say this: switching to a new clinic right after a rejection or denial is usually the wrong first move, and it can cost you money and weeks of time without changing Medicare’s answer.

A new clinic cannot make you eligible. It cannot invent records you do not have. It cannot talk CMS out of its own rules.

What a new provider can do is fill out paperwork your current office will not touch, review a denial that may be wrong, or become the prescriber when you truly need cash-pay care. Those are real problems, and they can be worth paying to solve. But you should know which problem you have before you hand anybody a credit card.

So we are going to do this in order. Free stuff first. Paid stuff last. If you never scroll past the free fixes, we have done our job.

Wait — was your Medicare GLP-1 Bridge request actually denied?

Answer: Not necessarily. A pharmacy rejection, a Medicare GLP-1 Bridge prior-authorization denial, and a regular Part D denial are three different events. A Bridge claim that reaches the prior-authorization step normally returns code 75 so the pharmacy can send the request to your prescriber; that is a handoff, not a decision that you failed.

CMS built the Bridge so an eligible first fill or drug switch goes through checks before the central processor asks for prior authorization. When those checks pass and authorization is needed, the pharmacy gets rejection code 75 and sends the request to the prescriber, usually within 24 to 72 hours. A claim sent to the wrong payer, sent with bad patient data, or written for an excluded product can also reject — but for a different reason and with a different fix.

Here are the three events, side by side.

Prior authorization means your prescriber has to answer CMS’s eligibility questions before the Bridge will pay. You do not complete or sign the clinical attestation yourself.

How to tell which one you have in one phone call. Call the pharmacy and ask three things:

1. What was the exact rejection code?
2. Which payer or processor did you send the claim to?
3. Did that rejection generate a Medicare GLP-1 Bridge prior-authorization request for my prescriber?

If the claim was supposed to go to the Bridge, the current routing is BIN 028918 and PCN MEDDGLP1BR. Do not try to direct the pharmacy’s billing yourself beyond giving them the CMS routing information. Ask the pharmacist to check the current CMS payer sheet and correct the claim.

If you are in this bucket, stop shopping for a new provider. First find out what the code says.

What does my Medicare GLP-1 Bridge rejection code mean?

Answer: The code tells you who owns the next move. Code 75 goes to the prescriber for prior authorization; code 70 points to the drug or product; codes tied to identity or eligibility need different fixes; and temporary processor errors should be resubmitted by the pharmacy.

CMS published a pharmacy reject-code reference tool. We regrouped its codes by the person who can fix them so you do not have to read a four-page claims document at the counter.

A code is not a diagnosis and it is not a final answer by itself. The full claim message matters. The pharmacy can call the Medicare GLP-1 Bridge Pharmacy Help Desk at 844-673-0910 when it needs help with submission or claim status.

→ Run the Denial Decoder if the code still does not tell you which door to use.

Source: CMS pharmacy guidance and reject-code reference tool.

Can you appeal a Medicare GLP-1 Bridge denial?

Answer: There is no formal appeal process inside the Medicare GLP-1 Bridge. CMS says a prescriber may resubmit the prior-authorization form when the original information was incorrect or when updated or additional information is available. A denial from your normal Part D plan is different and keeps the regular Part D exception and appeal process.

We know that sounds worse than it is. It is not.

A Bridge denial is not the end when the submitted facts were wrong or incomplete. Your prescriber can correct the form and send it back. CMS does not publish a guaranteed number of resubmissions or a special Bridge appeal deadline, so do not let anyone promise “unlimited appeals.” The safe, accurate request is simple: ask whether the denial reason can be answered with corrected, updated, or additional information.

You want the right process. For the Bridge, that process is resubmission — not a formal appeal.

Some online pages use the wrong word

Some pages call every second submission an “appeal.” CMS does not.

The difference matters because a formal Part D appeal has its own notices, deadlines, and review levels. A Bridge resubmission is the prescriber sending back a corrected or better-supported prior-authorization request. If you spend a week hunting for a Bridge appeal form, you will lose the week.

Ask any clinic this exact question:

“Do you mean a Medicare GLP-1 Bridge resubmission, or a formal Part D appeal?”

Those are different processes with different rules.

The good news buried in the fine print

The Bridge does not erase your normal Part D rights. If the prescription should be covered through your regular Part D plan, the plan must handle that request under Part D rules. The Bridge cannot be used as a reason to avoid a Part D coverage duty.

Translation: if your real problem is a Part D denial wearing a Bridge costume, use the Part D door. That is where formal coverage determinations, exceptions, and appeals live.

Source: CMS Medicare GLP-1 Bridge guidance for providers.

Why were you denied, and which door does that open?

Answer: Medicare GLP-1 Bridge denials and rejections come from a short list: the claim went to the wrong place, the drug or device was wrong, the submitted information was incomplete, the clinical criteria were not met, the plan type was not eligible, or the prescription belonged under regular Part D. Several of those problems can be fixed without paying a new clinic.

This is the table we would hand you across a kitchen table. Find your row.

The Bridge clinical rules in one table

The Bridge is not just “BMI 35 or higher.” CMS created three clinical lanes, and the BMI is measured when GLP-1 therapy was started.

The medication must also be prescribed for weight reduction or maintenance with ongoing nutrition and physical-activity changes that fit the FDA-approved label. The plan type, drug, formulation, prescription history, and Part D-covered uses still matter.

Check the starting-BMI date before you accept a low-BMI denial

Medicare looks at whether you met a Bridge clinical lane when you started GLP-1 therapy — not only at your BMI today.

CMS puts its own example in writing: a person who started GLP-1 therapy in September 2024 with a BMI of 37 and had a BMI of 34 when the July 2026 prior authorization was filed could still meet the BMI-35 lane. The prescriber should attest to the BMI at initiation.

That does not mean every low-BMI denial is wrong. It means the first question should be: Which date and record did the prescriber use?

If you paid cash before July 1, 2026 and your BMI is lower now, ask for the chart from the visit when therapy started. Then say:

“CMS measures the Bridge clinical criteria when GLP-1 therapy was initiated. Can you check the BMI and records from my starting date and resubmit if the first form used the wrong information?”

That sentence does not guarantee approval. It makes sure the right fact gets reviewed.

A Part D-covered use sends you to a different door — not an automatic approval

This is the part that surprises people.

Type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic MASH are excluded from the Bridge because GLP-1 treatment for those uses can fall under regular Part D. A prescription meant to reduce major cardiovascular event risk also belongs with the Part D plan.

That does not mean every Part D plan must approve every drug. Formularies, medical criteria, prior authorization, step requirements, exceptions, and appeals can still apply. But Part D has protections the Bridge does not.

Money you spend through the Bridge sits outside Part D. The $50 does not count toward your Part D deductible or true out-of-pocket costs. Regular covered Part D spending follows Part D rules instead.

KFF estimated that 9.7 million Medicare beneficiaries were enrolled in Part D and met the Bridge’s clinical criteria using 2023 claims data, but only about 3.8 million met all eligibility rules. That leaves about 5.9 million, or 61%, who failed at least one additional rule — such as a Part D-covered condition, a Part D GLP-1 fill in 2026, or another eligibility restriction. That does not tell us which reason affected each person, but it proves one thing: clearing the BMI test is not the same as clearing the full program.

You are not an unusual case. The extra filters remove more people than the final estimate includes.

Sources: CMS Bridge eligibility guidance and KFF’s eligibility analysis.

→ Use the free one-page re-file sheet

Two of the most common fixes are a correct record and one clear request to the prescriber. Print or copy this:

Medicare GLP-1 Bridge re-file sheet

1. Ask the pharmacy:

• What was the exact rejection code and full message?
• Was the claim sent to the Medicare GLP-1 Bridge central processor?
• Did the pharmacy send a prior-authorization request to my prescriber?

2. Ask the prescriber:

• Which BMI date did the form use?
• Did the form use my clinical status when GLP-1 therapy began?
• Was the correct drug and formulation listed?
• What exact reason did the Bridge give for the denial?
• Was any record, diagnosis, or required answer missing or wrong?

3. Use this sentence:

“CMS says a prescriber may resubmit the Medicare GLP-1 Bridge prior authorization when the original information was incorrect or when updated or additional information is available. Can you review the exact denial reason and resubmit if one of those conditions applies?”

4. Prescriber help: 855-273-0102, Monday through Friday, 8 a.m. to 7 p.m. Eastern.

5. Pharmacy help: 844-673-0910.

Privacy: Do not email your Medicare number, Social Security number, medical record, or denial letter to an ordinary support address. CMS tells people not to send protected health information through its general Bridge mailbox.

Read our full guide to providers that handle Medicare Bridge prior authorization if your office refuses to submit the form.

Medicare GLP-1 Bridge Denial Decoder

Use these five questions in order. Stop as soon as a row gives you a clear next move.

Question 1: What did you receive?

• A pharmacy message saying “PA required,” or code 75 → Your current prescriber should submit the Bridge prior authorization.
• A Bridge denial letter after the form was submitted → Go to Question 2.
• A coverage decision from your regular Part D plan → Use the Part D coverage and appeal process.
• Only the words “not eligible,” with no code or letter → Call the pharmacy and get the exact code and payer before doing anything else.

Question 2: Does the reason point to wrong, missing, or newer information?

• Yes → Ask your current prescriber to review and resubmit. If the office refuses, knownwell is the clearest public denial-review option we found.
• No, it says the plan or clinical rules were not met → Go to Question 3.
• You cannot tell → Ask the prescriber for the full denial reason. Do not guess from a portal summary.

Question 3: Was the drug prescribed for type 2 diabetes, moderate-to-severe sleep apnea, noncirrhotic MASH, or major cardiovascular event risk reduction?

• Yes → The prescription belongs under regular Part D, subject to your plan’s rules.
• No → Go to Question 4.
• Not sure → Ask the prescriber which FDA-approved use appears on the prescription and prior authorization.

Question 4: Is the drug and form covered by the Bridge?

• Foundayo, any current CMS-listed formulation → Go to Question 5.
• Wegovy injection or tablet listed by CMS → Go to Question 5.
• Zepbound KwikPen → Go to Question 5.
• Zepbound single-dose pen or vial → Ask whether a covered KwikPen prescription is medically appropriate. The Bridge does not cover the single-dose pen or vial.
• Another product → It is not on the current Bridge list.

Question 5: Will your current prescriber help?

• Yes → Stay with that prescriber. They already have your records.
• No, and the denial may be wrong → Check knownwell first; compare Sesame or Form Health for a new care relationship.
• No, and the denial is correct → Buy direct if you already have a prescription. Check Ro if you need an FDA-approved cash-pay prescriber.

Your result should never ask for: a Medicare number, Social Security number, full date of birth, denial-letter upload, prescription number, or medical record. This decoder identifies the right door. It does not determine medical eligibility or replace a clinician or CMS decision.

Can Medicare cover the doctor visit?

Answer: Medicare Part B can cover a specific obesity-screening and behavioral-counseling benefit at no cost when your BMI is 30 or higher, you receive it from a primary care doctor or other primary care provider in a primary care setting, and the provider accepts assignment. That does not make every GLP-1 prescribing visit, medication-management visit, telehealth visit, lab, or specialist visit free.

Almost nobody writing about GLP-1s and Medicare explains this narrow benefit, and it can change the math when your regular primary care office provides the covered service.

Medicare.gov says you pay nothing for the obesity-screening and behavioral-counseling service when your primary provider accepts assignment. The benefit can include:

• A weight screening and BMI check
• A dietary assessment
• Behavioral counseling once a week for the first month
• Counseling every other week in months two through six
• Monthly counseling in months seven through twelve if you have lost at least 6.6 pounds by the six-month visit
• Up to 22 covered face-to-face counseling sessions in a 12-month period under the current schedule

The conditions are specific. It must be the covered obesity-counseling service, delivered by an eligible primary care provider in a primary care setting. Other care may create a deductible, copay, coinsurance, or full self-pay charge. Call the office and ask:

“Will this appointment be billed as Medicare obesity screening and behavioral counseling, or as a separate medication-management or other medical visit? What will I owe?”

Now here is why that matters for your wallet

A telehealth membership usually does not create a lower manufacturer cash price for the drug. The membership buys access to a prescriber, follow-up care, support, and any services listed by the program. The medication charge is separate.

Run the numbers on Wegovy pen at the standard current manufacturer self-pay price of $349 for a 28-day box. The visit column below is intentionally not shown as automatically free, because only the specific Part B preventive benefit is $0 under its conditions.

That Wegovy row uses 13 boxes, not 12. One box of four weekly pens covers 28 days. Fifty-two weeks divided by four weeks is 13 boxes. Budgeting 12 boxes leaves one $349 box out.

If your current prescriber will write the prescription and the visit cost works for you, stop here. Use the re-file sheet, pursue the $50 Bridge if eligible, or compare manufacturer-direct cash pricing. Nothing below automatically beats that.

Keep reading only if your office said no, stopped prescribing, retired, or will not handle the Bridge paperwork.

Sources: Medicare.gov obesity behavioral therapy and CMS National Coverage Determination 210.12.

Can Medicare patients use LillyDirect and NovoCare cash prices?

Answer: Under the current terms we verified, Medicare beneficiaries can use the manufacturer self-pay pathways we list when they meet the program rules, pay outside insurance, and do not seek reimbursement or apply the spending to a deductible or true out-of-pocket total. That is different from the commercial copay cards, which exclude Medicare and other government coverage.

This confusion can cost hundreds of dollars a month, and it is genuinely not the patient’s fault.

We pulled the current manufacturer terms on August 5, 2026 and read the commercial and self-pay sections separately. Here is what they say.

The Cash-Pay Lockout Audit

Verified August 5, 2026 from NovoCare, Wegovy offer terms, Lilly’s Zepbound terms, and Lilly’s Foundayo full self-pay terms. Manufacturer programs can change or end without notice, so check the current terms again before paying.

Why so many pages get this backwards

The commercial savings card and the cash program can sit on the same manufacturer page.

The commercial card lowers the patient’s share when qualifying commercial insurance is part of the transaction. Medicare and other government coverage are excluded from that card.

The self-pay program is a different transaction. You pay cash outside insurance. The current terms we reviewed tell you not to seek reimbursement and not to count the charge toward a deductible or true out-of-pocket total. That language is exactly why a Medicare beneficiary must keep the cash purchase separate from Medicare.

Two manufacturers. Separate program sections. Different eligibility rules. Read the heading above the terms before deciding you are locked out.

The rule in plain words

A commercial savings card works with eligible commercial insurance. Medicare beneficiaries cannot use the commercial cards listed above.

A manufacturer self-pay program is a cash purchase under its own rules. In the current NovoCare Pharmacy, Zepbound, and Foundayo self-pay terms we audited, Medicare is not used to pay the claim, the patient cannot seek reimbursement, and the spending does not count toward Medicare deductible or TrOOP obligations.

That is not a permanent promise. Manufacturers can change pricing, eligibility, fill limits, refill windows, or expiration dates. Check the terms on the day you fill.

→ Buy it direct. We do not get paid for this.

If you already have a prescription, compare the manufacturer route before adding a telehealth membership:

• NovoCare Pharmacy for Wegovy
• LillyDirect for Zepbound
• Lilly Foundayo self-pay information

Those links do not pay us. We put them above the providers that may pay us because a willing prescriber plus manufacturer-direct pricing can be the simplest and least expensive cash path.

What will you actually pay after a Bridge denial?

Answer: Current manufacturer cash offers start at $149 a month for Wegovy pill or Foundayo and $299 for Zepbound. The active higher-dose offers top out at $449, but missing a 45-day Zepbound refill window can raise some doses to $499 or $699. A telehealth membership adds its own care fee because the medication is billed separately.

Every price below was checked at the manufacturer’s own site on August 5, 2026.

Bridge reminder: only the Zepbound KwikPen is included in the Medicare GLP-1 Bridge. The vial and single-dose pen may appear in cash-pay programs, but they are not Bridge-covered products.

Three cost traps nobody warns you about

The 45-day clock is real money. On Zepbound at 10, 12.5, or 15 mg, the difference between the current $449 Journey offer and the listed $699 regular price is $250 for one 28-day supply. Set a reminder before the window closes. On Foundayo 14.5 or 17.2 mg, missing the window raises the current price from $299 to $349.

A “month” may mean 28 days or 30 days. Wegovy pen and Zepbound use four weekly doses, which means 13 boxes or pensets cover 52 weeks. Wegovy pill and Foundayo define a month as 30 tablets or 30 days. Compare annual cost using the actual supply, not the word “monthly.”

Cash and Bridge spending do not count toward your Part D cap. Cash-pay purchases sit outside insurance. The $50 Bridge copay also sits outside Part D, does not apply to the Part D deductible, and does not count toward the $2,100 Part D out-of-pocket cap for 2026. Covered Part D spending follows a different set of rules.

A quick annual cash-price check

This is medication only. It does not include visits, labs, taxes, supplies, or membership fees.

The Foundayo terms still deserve a second look before a full-year budget. The self-pay card says it can be used for up to 10 fills per calendar year, while the separate Journey offer controls the $299 price for the two highest doses. Ask Lilly how those rules apply to your exact dose and fill schedule.

Sources: NovoCare Wegovy pricing and terms, Lilly Zepbound pricing and terms, and Lilly Foundayo pricing and terms.

What can a new provider actually fix?

Answer: A new provider can help when the problem is paperwork, missing records, a wrong prescription, an office that will not submit or resubmit, or the need for a new cash-pay prescriber. A new provider cannot change Medicare’s eligibility rules, create medical history that does not exist, or make an excluded drug or device Bridge-covered.

Before you pay anybody, check which list you are on.

A new provider may be able to help with this:

A new provider cannot fix this:

Anyone who promises to “get your denial overturned” before reading the reason is telling you something they cannot know. Approval depends on the program rules, accurate documentation, and medical appropriateness — not on how hard a clinic pushes.

The best GLP-1 provider after Medicare Bridge denial

Answer: For most people, the best GLP-1 provider after Medicare Bridge denial is the prescriber they already have because that office holds the records and may be able to correct the request without a new membership. When the office cannot or will not help, knownwell has the clearest public denial-review and resubmission workflow; Sesame has the lowest published starting care fee in this comparison; Form Health fits people who want ongoing Medicare obesity care; and Ro fits people who are correctly ineligible and need an FDA-approved cash-pay prescriber.

We scored two different jobs separately because “fix my Bridge request” and “prescribe an FDA-approved drug for cash” are not the same service.

For fixing a denial, we looked for a public Bridge-specific prior-authorization workflow, a public denial-review or resubmission process, Medicare participation, the ability to work from the patient’s history, fee clarity, and limits stated in plain language.

For cash pay after a correct denial, we looked for FDA-approved medication, transparent medication prices, transparent care fees, Medicare cash-pay eligibility, state availability, and a clear line between insurance support and cash service.

Affiliate payout is not in either score. It does not turn a cash-pay clinic into a denial specialist.

Provider sources: knownwell, Sesame, Form Health, and Ro.

Provider-stated vs. what we verified

This is the difference between “a provider says it helps with Medicare” and evidence that it handles the exact job on this page.

1. Your current prescriber — best for most people

Who it is for: Anyone whose office is willing to help. Especially if the issue is a starting-BMI date, a missing record, a code 75 handoff, a drug-form problem, or a routing error.

Why it wins: The office already has your history, diagnoses, and chart. It may be able to correct the request without a new intake or record transfer. CMS also says a provider does not have to be enrolled in Medicare to prescribe or submit a Bridge prior authorization, as long as the provider is not on Medicare’s Preclusion List.

The limitation: Medicare does not promise that every prescribing or medication-management visit is free. The narrow Part B obesity-counseling service may be $0 when its conditions are met, but other visits may have cost sharing or a self-pay charge. Some offices also do not prescribe weight-loss drugs or have not learned the Bridge process.

What to say if the office pushes back:

“I am asking about the Medicare GLP-1 Bridge, not ordinary weight-loss coverage under my Part D formulary. The prior authorization goes through the Bridge central processor. Can your office review the CMS form, use the clinical information from when I started therapy, and submit or resubmit it if the CMS rules allow?”

No link here. No commission. Make the call first.

2. knownwell — best when your denial might be wrong

Who it is for: You received a completed Bridge denial, the reason may be wrong or incomplete, and your current office will not chase it.

What knownwell publicly describes doing: its Medicare Bridge page says the care team reviews the reason for a denial. If the denial looks like an error or improper rejection, knownwell says it contacts Humana to confirm and resubmit the prior authorization. Of the new providers we compared, that is the clearest public description of a denial-specific workflow.

Stated plainly: knownwell cannot make an ineligible person eligible. It cannot promise that a denial is wrong. Your plan participation, state availability, records, and visit cost still have to be confirmed. And if anyone uses the word “appeal,” ask whether they mean a Bridge resubmission or a formal Part D appeal.

Best for: a completed denial that looks like a paperwork or documentation problem after the original office has stopped helping.

→ See whether knownwell can review your denial — confirm Medicare participation, state availability, records needed, and expected visit cost before you book.

3. Sesame — lowest published starting total here if the Bridge approves you

Who it is for: You may qualify for the Bridge, but you need a new provider to evaluate you and submit the paperwork.

Sesame has a Medicare-specific GLP-1 page. It says the provider confirms the Medicare details and handles the prescription paperwork. Success by Sesame starts at $59 a month with an annual subscription, and the page lists video visits, messaging, and labs. The Bridge medication is $50 per monthly supply if approved.

Sesame lists the current Bridge products: Foundayo, Wegovy injection and tablets, and Zepbound KwikPen. CMS says an approved Bridge prior authorization stays valid through December 31, 2027, and a dose change within the same covered drug does not require a new PA; switching to another covered drug does.

Stated plainly: $109 is not a guaranteed all-in price. It assumes the $59 subscription tier and Bridge approval. The care fee is separate and may remain due even when the medication is not approved. Sesame’s public page confirms submission help, but we did not find a public promise that a Sesame provider will take over and resubmit a denial filed by another office. Ask before enrolling for that exact job.

Best for: a new Bridge evaluation and submission when the original prescriber will not participate, especially when the $59 annual-subscription structure fits.

→ See Sesame’s Medicare GLP-1 program and check the current terms

4. Form Health — best if you want an ongoing Medicare obesity-care team

Who it is for: You want physician-led obesity care that can be billed to Medicare when covered, not only a one-time prescription request.

Form Health announced on July 1, 2026 that it had begun prescribing through the Medicare GLP-1 Bridge. Form says it has long accepted Medicare and uses physician-led care with obesity-medicine clinicians and multidisciplinary support.

Two things to know before you start: Form’s FAQ says patients need an existing primary care provider they have seen within the last 12 months. When insurance does not cover the Form program, its published self-pay plan is $299 a month for clinician and dietitian care, messaging, and platform access; medication and lab work are separate.

Stated plainly: Form publicly confirms Bridge participation and the prior-authorization role, but we did not find a public promise that it will take over and resubmit a Bridge denial another provider filed. Ask that exact question before transferring records.

Best for: ongoing obesity care with a full clinical team, subject to plan, state, and coverage.

A patient quote published by Form says the team was “pleasant, available and professional.” That describes one patient’s service experience. It is not a promise of approval or a medical result.

→ Check Form Health’s Medicare and Bridge information

5. Ro — best when the denial is correct and you need a cash-pay prescriber

Who it is for: You do not qualify for the Bridge, you want an FDA-approved medication, and you need a clinician to evaluate and prescribe it.

That refund promise matters when your fear is paying for an intake and being told no. It does not guarantee that any medication will be prescribed.

Here is the honest limitation, and it is specific. We found no public Ro promise to submit or resubmit the Medicare GLP-1 Bridge prior authorization. Ro has broader insurance support, but its own page places Medicare users in certain cash-pay options. If your Bridge request may still be fixed, your current prescriber, knownwell, Sesame, or Form is the better door. Ro becomes useful after there is no Bridge or Part D coverage left to fight for.

One billing point to know: Ro memberships renew under the selected plan. Ro’s terms say to cancel at least 48 hours before the next renewal to avoid another membership charge. The $39 eligibility refund does not turn every later membership payment into a refundable trial.

One customer wrote, “Process was quick and easy,” in an invited Trustpilot review. That is about one signup experience, not approval, safety, weight loss, or a typical result.

→ Check Ro eligibility and current cash pricing — the $39 first month is refunded if the Ro provider finds you are not eligible for GLP-1s. Medication is separate.

Who we are not recommending on this page, and why

Compounded semaglutide and tirzepatide. We are leaving them out of the Bridge and FDA-approved cash-pay comparison.

Compounded drugs are not part of the Medicare GLP-1 Bridge. They are not FDA-approved, and FDA does not review them before marketing for safety, effectiveness, or quality. They also should not be described as approved generics, as “the same” as an FDA-approved drug, or as a direct Bridge replacement.

The current Bridge products are brand-name, FDA-approved products. This page is about getting the correct Medicare route or comparing FDA-approved manufacturer cash options after that route is closed. Putting compounded products in the same winner table would blur a line that should stay clear.

A licensed clinician may discuss compounding in a separate patient-specific situation when the law and medical facts support it. That is a different decision, not a Medicare Bridge path.

Source: FDA — Compounding and FDA: Questions and Answers.

Which option fits your exact situation?

Answer: The right choice depends on the exact rejection or denial, whether the current prescriber will help, which drug and formulation were ordered, why the medication is being prescribed, and whether you truly qualify. Here are the common situations and the single best first move for each.

“My BMI is lower now than when I started.” → Your current prescriber. Ask which starting date and record were used. CMS measures the clinical criteria at therapy initiation, so a request that used only today’s BMI may need corrected information.

“My doctor will not fill out the form.” → knownwell if a completed denial may be wrong. Sesame if you need a new clinician to evaluate you and make a new Bridge submission. Form Health if you want an ongoing obesity-care team. Ask each provider whether it will handle your exact stage before paying.

“The pharmacy sent it to my Part D plan.” → The pharmacy. Ask it to check whether the prescription belongs under regular Part D or should be routed to the Bridge at BIN 028918 and PCN MEDDGLP1BR. Do not pay a new provider merely to correct a billing route.

“The pharmacy gave me code 75.” → Your current prescriber. That code means prior authorization is required. Ask whether the PA arrived and when it will be submitted.

“The pharmacy gave me code 70.” → Your prescriber and pharmacist. It points to a product or NDC problem. Confirm that the prescription is for Foundayo, a current Wegovy formulation, or Zepbound KwikPen when the Bridge is the intended route.

“The pharmacy gave me code 65.” → Get the full message. Code 65 can reflect different eligibility or record stops, so “code 65” alone is not enough to tell you whether the fix belongs to the pharmacy, Medicare records, the plan, or the prescriber.

“I was prescribed a Zepbound single-dose pen or vial.” → Your current prescriber. Only the KwikPen is included in the Bridge. Ask whether a KwikPen prescription is medically appropriate. Do not switch products on your own.

“I have type 2 diabetes, moderate-to-severe sleep apnea, or MASH.” → Your regular Part D plan and treating clinician. The Bridge is not the correct payment path for those Part D-covered uses. Coverage is still subject to the plan’s formulary and criteria.

“The drug is for heart-attack or stroke risk reduction.” → Your regular Part D plan. CMS says a prescription written to reduce major cardiovascular event risk should go to Part D, even when weight management is also a goal.

“I want a full care team and I want Medicare billed when covered.” → Form Health or knownwell. Confirm plan participation, state availability, expected cost sharing, and whether the provider will handle an existing denial.

“I know I do not qualify, and I already have a prescription.” → Compare NovoCare for Wegovy and Lilly’s current self-pay programs before buying another membership.

“I know I do not qualify, and I need a prescriber.” → Ro is the strongest FDA-approved cash-pay telehealth fit on this page. Compare its care fee plus medication price against other cash-pay GLP-1 paths for Medicare beneficiaries.

“I am afraid of needles.” → Do not jump from a Medicare denial to a compounded pill. The Bridge currently includes Wegovy tablets and Foundayo tablets. Ask a prescriber whether either FDA-approved oral option fits your medical situation.

“I am not sure whether the denial is final.” → Run the Denial Decoder, then take the matching script to the pharmacy or prescriber.

“None of these routes fits.” → Review Medicare GLP-1 Bridge alternatives or use the matching quiz at the bottom of this page. Do not force yourself into a provider built for a different problem.

What we actually verified

Answer: We checked the Bridge rules at CMS and Medicare.gov, the cash prices and program terms at the manufacturers, and the provider claims on each provider’s own site. We kept program rules, company-stated commercial facts, and our editorial fit judgments separate so a marketing promise never gets presented as a Medicare rule.

Every commercial page we publish carries this box. Here is what we checked, when, and what remains unknown.

Verified at CMS and Medicare.gov on August 5, 2026

• The Bridge runs from July 1, 2026 through December 31, 2027.
• Eligible Bridge drugs cost the beneficiary $50 per monthly supply.
• The Bridge sits outside Part D: the Part D deductible does not apply, the $50 does not count toward TrOOP, Extra Help does not reduce it, and coupons or discount programs cannot be applied to Bridge claims.
• Current products are all CMS-listed Foundayo formulations, all CMS-listed Wegovy injection and tablet formulations, and Zepbound KwikPen only.
• Zepbound single-dose pens and vials are not Bridge-covered, and Bridge does not pay for KwikPen needles.
• CMS uses Humana as the 2026 central processor and lists BIN 028918 / PCN MEDDGLP1BR.
• There is no formal Bridge appeal. A prescriber may resubmit when the original information was incorrect or when updated or additional information is available.
• The PA request is generally sent to the prescriber within 24 to 72 hours, and a decision is sent within 72 hours after submission.
• Bridge clinical criteria use the patient’s status when GLP-1 therapy was initiated.
• Type 2 diabetes, moderate-to-severe obstructive sleep apnea, noncirrhotic MASH, and prescriptions for major cardiovascular event risk reduction belong under regular Part D rather than the Bridge.
• A Part D denial is not required before a claim is sent to the Bridge.
• A prescriber does not have to be Medicare-enrolled for the Bridge but cannot be on the Medicare Preclusion List.
• Medicare Part B may cover a separate obesity-screening and behavioral-counseling benefit at $0 when its narrow eligibility, provider, setting, and assignment rules are met. We did not treat all GLP-1 visits as free.

Verified at manufacturer sites on August 5, 2026

• Wegovy pill cash pricing: $149 at 1.5 mg; $149 at 4 mg through August 31, 2026, then $199; $299 at 9 mg and 25 mg.
• Wegovy pen cash pricing: $199 for each of the first two qualifying new-patient 0.25 mg or 0.5 mg fills through December 31, 2026; then $349 for standard doses; $399 for Wegovy HD 7.2 mg.
• Zepbound self-pay: $299 at 2.5 mg, $399 at 5 mg, and $449 at 7.5–15 mg under the current Journey offer; regular prices can reach $699 when the 45-day rule is missed.
• Foundayo self-pay: $149 at 0.8 mg, $199 at 2.5 mg, $299 at 5.5 mg and 9 mg, and a $299 Journey price for 14.5 mg and 17.2 mg when the 45-day rule is met; the regular top-dose price is $349.
• The current Foundayo self-pay card says up to 10 fills per calendar year and expires December 31, 2026.
• The commercial savings cards exclude Medicare. The current manufacturer self-pay terms operate outside insurance and prohibit reimbursement or TrOOP credit rather than using the commercial cards’ blanket Medicare exclusion.

Verified at provider sites on August 5, 2026

• knownwell publicly says it reviews a Bridge denial, contacts Humana when the denial appears wrong, and resubmits the prior authorization.
• Sesame publicly lists a Medicare Bridge pathway, provider paperwork, a care membership starting at $59 a month with an annual subscription, and a $50 Bridge medication cost if approved.
• Form Health publicly announced Bridge prescribing on July 1, 2026, says it accepts Medicare, and lists a $299 monthly self-pay care plan when insurance does not cover the program; medication and labs are separate.
• Ro lists $39 for the first month, then $149 monthly or as low as $74 monthly with an annual plan paid upfront. Medication is separate. Ro says the first $39 is refunded if its provider finds the patient is not eligible for GLP-1s.
• Ro says Medicare and Medicare supplement members may be eligible for certain cash-pay options. Ro’s public materials did not give us a Bridge-specific submission or resubmission promise.

What we could not confirm — and will not guess at

• Whether Form Health or Sesame will take over and resubmit a Bridge PA another office already filed and lost.
• The exact patient cost for knownwell or Form Health under each Medicare plan and network.
• Approval rates, denial-resubmission success rates, or a guaranteed response time for any provider.
• Live pharmacy stock.
• Whether a provider can obtain the old records needed for one specific patient.
• What manufacturer prices and terms will be after their current offer dates.
• What CMS will replace the Bridge with after December 31, 2027.

How we built the original comparison

We did not use one generic “best provider” score. We built two decision paths:

1. Denial-resolution path: current prescriber → denial-specific review and resubmission evidence → new Bridge submission support.
2. Confirmed-ineligible path: manufacturer-direct prescription → FDA-approved cash-pay telehealth when a prescriber is needed.

We then assembled four source types that no single competing page puts together in this form:

• the official Bridge claim and rejection-code workflow;
• the official clinical, plan, drug, and formulation rules;
• the manufacturer commercial-card versus self-pay terms;
• the provider-stated versus verified denial-handling table.

That is our editorial work. The underlying program and price facts belong to CMS, Medicare, the manufacturers, and the providers, and every source is listed below.

Money disclosure

We may earn a commission if you sign up with a provider through a sponsored link. We earn nothing when you keep your current prescriber, use your regular Part D plan, or buy directly from NovoCare or LillyDirect. Those no-commission paths still appear first when they fit the problem better.

Common questions after a Medicare GLP-1 Bridge denial

Answer: The questions below close the gaps that most often send people back to the pharmacy, a plan website, or another article. Each answer starts with the action that matters most.

Is the first pharmacy rejection a Medicare GLP-1 Bridge denial?

Usually not. When a claim clears the Bridge’s preliminary checks and needs prior authorization, the central processor returns code 75 so the pharmacy can send the PA request to the prescriber. Ask whether code 75 was returned and whether the request reached the office.

Can I appeal a Medicare GLP-1 Bridge denial?

There is no formal appeal inside the Bridge. CMS says a prescriber may resubmit the form if the original information was incorrect or if updated or additional information is available. A regular Part D denial is different and follows Part D’s coverage and appeal rules.

How many times can my prescriber resubmit?

CMS does not publish a guaranteed resubmission count or a special Bridge resubmission deadline. Do not rely on claims of “unlimited appeals.” Ask whether the next submission contains corrected, updated, or additional information that answers the actual denial reason.

Does my starting BMI count, or only my BMI today?

The starting point matters. CMS says the clinical criteria are measured when GLP-1 therapy was initiated. Its example shows a person who began at BMI 37 and later reached BMI 34 could still meet the BMI-35 lane when the prescriber accurately attests to the starting status.

What are the actual Bridge BMI rules?

There are three lanes: BMI 35 or higher; BMI 30 or higher with one of CMS’s listed conditions; or BMI 27 or higher with one of another listed group of conditions. Meeting a BMI lane is not enough by itself. Plan type, prescription use, product, prior Part D fills, and other rules still apply.

Does the $50 Bridge cost count toward my $2,100 Part D cap?

No. The Bridge operates outside Part D. The $50 does not count toward the Part D deductible or true out-of-pocket total, and Extra Help does not lower the Bridge amount.

Does the $50 include the doctor visit?

No. The $50 is for the Bridge medication supply. A separate visit may be covered, create Medicare cost sharing, or be self-pay. Medicare’s $0 obesity-counseling benefit is a specific preventive service with its own BMI, provider, setting, and assignment rules.

Can I use a manufacturer coupon with the Bridge?

No. CMS says coupons and discount programs cannot be applied to Bridge claims. Manufacturer self-pay pricing is a separate cash transaction outside the Bridge and outside insurance.

Is every form of Zepbound covered?

No. Only Zepbound KwikPen is included in the Bridge. The single-dose vial and single-dose pen are excluded. Ask the prescriber whether a KwikPen is medically appropriate rather than assuming the pharmacy can swap the product.

Are Zepbound KwikPen needles covered?

No. CMS says pen needles are not covered by the Bridge and should not be billed to the Bridge or the patient’s Part D plan. Patients may have to buy the needles separately.

Are all forms of Wegovy and Foundayo covered?

CMS currently says all listed formulations of Wegovy and Foundayo are included. The exact NDC list can change, so the pharmacy should check the current CMS table when code 70 appears.

Does my prescriber have to accept Medicare?

Not to write the Bridge prescription or submit the Bridge PA. CMS says the provider does not have to be enrolled in Medicare but cannot be on the Preclusion List. Whether Medicare pays for the visit is a separate question.

Does the pharmacy have to sign up for the Bridge?

No. CMS says pharmacies do not opt into a special Bridge network. A pharmacy that is confused can review the payer sheet or call the Pharmacy Help Desk at 844-673-0910.

Do I need a Part D denial before using the Bridge?

No. CMS says the prescriber may direct the pharmacy to send an appropriate claim straight to the Bridge. A Part D denial is not a prerequisite.

What if my prescription is for diabetes, sleep apnea, MASH, or cardiovascular risk reduction?

Use the normal Part D route. Those uses may be eligible for Part D coverage, subject to the plan’s formulary and requirements. Being routed to Part D is not a guarantee that the first claim will be approved.

What if I filled a GLP-1 through Part D earlier in 2026?

The current 2026 Bridge rules make a beneficiary ineligible for the Bridge in that calendar year after a Part D-covered GLP-1 fill. CMS has not used that rule to say that a cash purchase by itself creates the same exclusion.

If I pay cash now, will that ruin a future Bridge request?

A cash purchase is not the same as a Part D-paid fill. CMS also says clinical eligibility can be measured when therapy began before the Bridge launched. Keep your starting records, do not submit self-pay spending for Medicare reimbursement, and recheck all program rules before a later request.

Does an approved Bridge PA last through the whole program?

CMS says an approved PA remains valid through December 31, 2027. A dose change within the same covered drug does not require a new PA. Switching from one covered Bridge drug to another requires a new PA.

Does Ro handle Medicare GLP-1 Bridge paperwork?

We found no public Ro promise to submit or resubmit a Bridge-specific PA. Ro is placed here as an FDA-approved cash-pay option for Medicare users who may qualify for cash treatment after coverage routes are closed, not as a Bridge-denial specialist.

Can Sesame file Medicare Bridge paperwork?

Sesame’s public Medicare page says its provider handles the prescription paperwork and lists the Bridge medication at $50 if approved. We did not find a public promise that Sesame will take over an already-denied PA filed by another provider, so ask before paying for that purpose.

Is knownwell the best new provider after a Bridge denial?

It is the strongest new-provider fit we found for a potentially incorrect completed denial because knownwell publicly describes reviewing the reason, contacting Humana when the denial looks wrong, and resubmitting. Your current prescriber still comes first when that office will help.

What if code 65 appears?

Ask the pharmacist for the full response text. Code 65 can point to different eligibility or record problems, including plan or patient-status edits. The number alone does not tell you whether a new provider will help.

What if the pharmacy says the processor is down?

Code 85 is a temporary processor-unavailable message. The pharmacy should resubmit later. It is not a clinical denial and is not a reason to buy another program.

Can I get a 60-day or 90-day Bridge supply?

No. CMS says the Bridge pays for one monthly supply at a time — 28 days for weekly injections and 30 days for daily tablets. Ask the pharmacy about the next fill date instead of requesting a 60-day or 90-day claim.

What if my Bridge medicine was lost, stolen, or I am traveling?

CMS says the Bridge does not provide a lost-or-stolen medication override. A vacation override may be available when the pharmacy submits it under the CMS instructions. Call the pharmacy before travel and ask it to check the current Bridge override rules.

Can I wait for BALANCE instead?

CMS says the BALANCE Model will not launch in Medicare Part D in 2027. The Bridge was extended through December 31, 2027 while CMS gathers more data ahead of possible later Part D implementation. There is no announced 2027 BALANCE enrollment path to wait for.

What happens after December 31, 2027?

CMS has not announced the final replacement or coverage structure. Treat the Bridge end date as a real planning limit, but do not assume a specific next program until CMS publishes it.

Is Foundayo really $149 to $299 for cash patients?

Those are the current self-pay prices for the listed doses, but the details matter. The top two doses require the 45-day Journey rule to stay at $299, the regular top-dose price is $349, the current card allows up to 10 fills per calendar year, and the terms expire December 31, 2026 unless changed.

Is Ro’s $39 price the medication price?

No. It is the first-month membership charge. Medication is separate. Ongoing membership is $149 monthly or as low as $74 monthly with an annual plan paid upfront.

Can I use a compounded GLP-1 instead?

That is a separate medical and regulatory decision. Compounded drugs are not part of the Bridge and are not FDA-approved. Do not treat them as approved generics or as the same product. Discuss any individual need with a licensed clinician.

One last thing

If you take nothing else from this page, take this: call your prescriber’s office before you call anybody else.

Ask what the exact rejection or denial said. Ask which BMI date the form used. Ask whether the claim went to the Bridge or Part D. Ask whether corrected, updated, or additional information can answer the denial reason.

That call may save you a new intake, a monthly membership, and weeks of starting over.

And if the answer comes back no — a real no, for a real reason — you now know what the FDA-approved cash programs cost, what their timing rules are, and which provider fits the job you actually need done.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Sources

1. CMS — Medicare GLP-1 Bridge: Information for Providers
2. CMS — Medicare GLP-1 Bridge: Information for Pharmacies
3. CMS — Medicare GLP-1 Bridge: Information for Part D Plans
4. CMS — Medicare GLP-1 Bridge Pharmacy Reject Code Reference Tool
5. Medicare.gov — Obesity behavioral therapy
6. Medicare.gov — Weight-loss drugs
7. CMS — Final CY 2026 Part D Redesign Program Instructions
8. KFF — Estimated eligibility for the Medicare GLP-1 Bridge
9. NovoCare — Wegovy savings and self-pay pricing
10. Lilly — Zepbound coverage and self-pay terms
11. Lilly — Foundayo coverage, self-pay pricing, and full terms
12. knownwell — Prior authorization and Medicare Bridge denial workflow
13. Sesame — Medicare GLP-1 Bridge care page
14. Form Health — Medicare GLP-1 Bridge announcement
15. Form Health — Program FAQ and self-pay terms
16. Ro — Weight-loss program pricing
17. Ro — Insurance and government-plan cash-pay information
18. Ro — Terms of use and cancellation timing
19. FDA — Compounding and FDA: Questions and Answers
20. Trustpilot — Ro customer reviews
21. Form Health — Patient service testimonials

This page is for information only and is not medical advice. Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We are not affiliated with CMS, Medicare, Humana, Novo Nordisk, or Eli Lilly. Program rules, provider availability, prices, and offer terms can change. Check the current source before acting.